Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Name: Αlpha¹ Rigor Record — Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Item: Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Rating: 59
Author: Αlpha¹

Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 3 high issues for “Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
StatisticsStatistic did not reproduce−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies3

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Reported statistics do not recomputeRecomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 3 trial with strong scientific premise, rigorous design, and transparent reporting. The main weaknesses are the lack of a clear data availability statement and a p-value inconsistency in the primary analysis that warrants verification.

Both reviewers agreed on study type (interventional). The statistics verification component recomputed only a subset of reported tests; the p-value discrepancy is a specific finding. Other dimensions were assessed based on full-text review.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 2 tests: 1 consistent, 1 inconsistent; 2 via agent-written checks. 1 printed percentage that does not match its own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies showing improved outcomes with BV-AVD and the efficacy of PD-1 blockade in cHL, and acknowledges limitations such as toxicity and relapse. The rationale for comparing N-AVD to BV-AVD is clearly stated, and the study addresses gaps by including a broader age range and diverse population.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise by citing prior work on BV-AVD and PD-1 blockade, and provides a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraph 1]

“The incorporation of the CD30-directed antibody drug conjugate, brentuximab vedotin (BV), into treatment of advanced stage cHL has led to improved outcomes.”